FDA grants clearance to AI-powered imaging system

The FDA has granted 510(k) clearance for technology that uses AI to enhance images from shorter scan procedures.

California-based medical device company Subtle Medical announced the clearance of its SubtlePET platform in a press release on Wednesday, Dec. 5. The platform integrates deep-learning algorithms with any original equipment manufacturer (OEM) scanner and picture archiving communication (PAC) system to enhance images during acquisition without interrupting or altering a radiologist’s workflow, according to the release.

The company believes the AI platform will help hospitals complete more exams daily and reduce the amount of time a patient spends in a scanner, which will hopefully lead to an improved patient experience.

"This FDA clearance is a key milestone in Subtle Medical's mission to bring novel and empathetic deep learning to improve patient satisfaction," Enhao Gong, PhD, founder and CEO of Subtle Medical, said in a prepared statement. "Our focus on image acquisition and workflow differentiates us from other AI companies that are working on post-processing and computer-aided diagnosis products. We are not replacing radiologists––we are addressing the tremendous cost to U.S. healthcare by leveraging deep learning in imaging at the infrastructure level to enable better and higher quality care."

Radiologists workflows were among the many topics of discussion during the annual RSNA meeting last month in Chicago. During one of the presentations, Penn Medicine physician William W. Boonn, MD, called for the inclusion of two-way communication when it comes to adopting AI into radiologists' workflows.

“In order for us to develop workflows that are actually going to be used by radiologists, we need to break down some of these silos and enable better communication, better integration between the two,” Boonn said.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.